4.5 Article

Alternative treatment modality for severe aplastic anemia in a resource-limited setting: a single-institution prospective cohort study from Upper Egypt

Related references

Note: Only part of the references are listed.
Article Hematology

Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study

Bhavisha A. Patel et al.

Summary: Patients with severe aplastic anemia (SAA) are treated with bone marrow transplant (BMT) or immunosuppression (IST) depending on individual factors. The addition of eltrombopag (EPAG) to standard IST for SAA improves hematologic responses. However, the rates and characteristics of long-term complications, relapse, and clonal evolution with this new regimen are not yet known. This study reports a cumulative relapse rate of 39% in responding patients and a clonal evolution rate of 15% in all treated patients at 4 years. Relapse occurred at distinct timepoints and most relapsed patients responded to retreatment. Clonal evolution to high-risk abnormalities was noted in 5.7% of patients and was associated with poorer overall survival.

BLOOD (2022)

Article Oncology

Eltrombopag in children with severe aplastic anemia

Harry Lesmana et al.

Summary: This study evaluated the efficacy and safety of standard immunosuppressive therapy and combination therapy with eltrombopag in pediatric severe aplastic anemia patients. The results showed a higher objective response rate in the treatment group with eltrombopag added, and no significant differences in infections between the two therapies.

PEDIATRIC BLOOD & CANCER (2021)

Article Oncology

Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children

Ma Jie et al.

Summary: The study evaluated the efficacy and safety of eltrombopag as a first-line therapy in pediatric patients with aplastic anemia. Results showed significantly increased complete response rates without intolerable side effects compared to historical cohort after 6 months of treatment.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2021)

Article Oncology

Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study

Meixin Fang et al.

Summary: The study found that the combination of E-PAG and IST therapy was more effective than IST alone in the treatment of pediatric SAA after 6 months, with good tolerability and compliance.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2021)

Article Pharmacology & Pharmacy

Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia

Mary B. Wire et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

Article Medicine, General & Internal

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Danielle M. Townsley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Editorial Material Hematology

Eltrombopag: a stem cell cookie?

Judith C. W. Marsh et al.

BLOOD (2014)

Article Pediatrics

Acquired Aplastic Anemia in Children

Helge D. Hartung et al.

PEDIATRIC CLINICS OF NORTH AMERICA (2013)

Review Hematology

How I treat acquired aplastic anemia

Phillip Scheinberg et al.

BLOOD (2012)

Article Medicine, General & Internal

Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

Matthew J. Olnes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia

Phillip Scheinberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Review Virology

Hepatitis Associated Aplastic Anemia: A review

Bisma Rauff et al.

VIROLOGY JOURNAL (2011)

Review Hematology

Clinical management of aplastic anemia

Amy E. DeZern et al.

EXPERT REVIEW OF HEMATOLOGY (2011)

Article Hematology

Aplastic Anemia: Pathophysiology and Treatment

Neal S. Young et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)

Article Hematology

Treatment of pure red-cell aplasia and aplastic anaemia with Ciclosporin: Long-term clinical effects

Thomas H. Tötterman et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2010)

Review Hematology

Guidelines for the diagnosis and management of aplastic anaemia

Judith C. W. Marsh et al.

BRITISH JOURNAL OF HAEMATOLOGY (2009)

Article Pharmacology & Pharmacy

Eltrombopag

Karly P. Garnock-Jones et al.

DRUGS (2009)

Review Oncology

Acquired Aplastic Anemia in Childhood

Eva C. Guinan

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)

Article Hematology

Epidemiology of aplastic anemia: a prospective multicenter study

Eva Montane et al.

HAEMATOLOGICA (2008)

Review Hematology

Historical review: megakaryopoiesis and thrombopoiesis

Kenneth Kaushansky

BLOOD (2008)

Article Cell & Tissue Engineering

Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells

Hong Qian et al.

CELL STEM CELL (2007)

Article Medicine, General & Internal

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura

James B. Bussel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Hematology

The epidemiology of aplastic anemia in Thailand

S Issaragrisil et al.

BLOOD (2006)

Article Medicine, General & Internal

Cyclosporine monotherapy for severe aplastic anemia: a developing country experience

J Al-Ghazaly et al.

ANNALS OF SAUDI MEDICINE (2005)